Deutsche Bank AG decreased its holdings in Tocagen Inc (NASDAQ:TOCA) by 33.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,167 shares of the company’s stock after selling 27,069 shares during the period. Deutsche Bank AG owned about 0.23% of Tocagen worth $66,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in TOCA. Goldman Sachs Group Inc. raised its stake in Tocagen by 112.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 48,947 shares of the company’s stock valued at $26,000 after buying an additional 25,880 shares during the period. Geode Capital Management LLC increased its stake in shares of Tocagen by 13.3% during the fourth quarter. Geode Capital Management LLC now owns 329,250 shares of the company’s stock worth $175,000 after purchasing an additional 38,620 shares during the period. Finally, Nuveen Asset Management LLC bought a new position in shares of Tocagen during the first quarter worth approximately $50,000. Hedge funds and other institutional investors own 21.42% of the company’s stock.
Shares of NASDAQ TOCA opened at $15.05 on Tuesday. The firm has a market cap of $359.98 million, a P/E ratio of -6.35 and a beta of 0.01. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 1.88. Tocagen Inc has a 1-year low of $0.42 and a 1-year high of $6.77. The business’s 50 day moving average is $5.09 and its 200-day moving average is $2.07.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Thursday, April 23rd. The company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.01. Tocagen had a negative return on equity of 327.74% and a negative net margin of 176,433.34%. Analysts forecast that Tocagen Inc will post -2.65 EPS for the current year.
Separately, Zacks Investment Research lowered Tocagen from a “buy” rating to a “hold” rating in a research note on Wednesday, June 10th. Eight investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Tocagen currently has a consensus rating of “Hold” and an average target price of $1.71.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
See Also: What is an overbought condition?
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.